Differential impact of glucagon-like peptide-1 (GLP-1) receptor agonists for weight loss in the type 2 diabetic and non-diabetic populations.

Jia IT, Bloomfield GC, Chen MY, Cunningham MH, Wang A, Daly SC, Hinojosa MW, Smith BR, Nguyen NT, Azagury DE, Prindeze NJ

Surgical endoscopy8 Jun 2026

PMID42260171DOI10.1007/s00464-026-12940-0PepBankPUB-42260171

Publisher page PubMedAsk about this study

Jump to 16 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study16

2 results from studies that gave the peptide. 2 results from people.

01HumanSystematic reviewEfficacy outcome
In a meta-analysis of populations with and without diabetes, semaglutide was associated with significantly greater adjusted weight-reduction magnitude than liraglutide (beta +1.67; P<0.001).
In plain wordsIn a review of people with and without diabetes, semaglutide was linked to greater adjusted weight reduction than liraglutide.
Peptide
Semaglutide
Outcome
IncreaseMagnitude of adjusted weight reduction versus liraglutide
Study
n: not reported in source
Comparator
Liraglutide
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated
Measurements
Beta
1.67
semaglutide versus liraglutide; P<0.001
Source sentences
Summary
Semaglutide produced significantly greater reductions than liraglutide after adjustment (β = + 1.67, p < 0.001), while baseline BMI was inversely associated with percent weight change (β = + 0.46, p < 0.001).
3 context sentences(design, population, supporting numbers)
Summary · context
This study represents a subgroup analysis of a large-scale meta-analysis including clinical trials, observational and case-control studies published from 2010 to 2025 reporting long-term weight outcomes for GLP-1 agents.
Summary · context
Outcomes were evaluated across mixed, intention-to-treat (ITT), and treatment-adherent populations and stratified by diabetes status.
Summary · context
Mixed-effects meta-regression was performed to evaluate independent predictors of weight loss.
Report a problemFND-4226017111
02HumanSystematic reviewEfficacy outcome
In a meta-analysis of populations with and without diabetes, liraglutide was associated with less adjusted weight-reduction magnitude than semaglutide; beta +1.67 was reported for semaglutide versus liraglutide (P<0.001).
In plain wordsIn a review of people with and without diabetes, liraglutide was linked to less adjusted weight reduction than semaglutide.
Peptide
Liraglutide
Outcome
DecreaseMagnitude of adjusted weight reduction versus semaglutide
Study
n: not reported in source
Comparator
Semaglutide
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated
Measurements
Beta
1.67
semaglutide versus liraglutide; P<0.001
Source sentences
Summary
Semaglutide produced significantly greater reductions than liraglutide after adjustment (β = + 1.67, p < 0.001), while baseline BMI was inversely associated with percent weight change (β = + 0.46, p < 0.001).
3 context sentences(design, population, supporting numbers)
Summary · context
This study represents a subgroup analysis of a large-scale meta-analysis including clinical trials, observational and case-control studies published from 2010 to 2025 reporting long-term weight outcomes for GLP-1 agents.
Summary · context
Outcomes were evaluated across mixed, intention-to-treat (ITT), and treatment-adherent populations and stratified by diabetes status.
Summary · context
Mixed-effects meta-regression was performed to evaluate independent predictors of weight loss.
Report a problemFND-4226017116

Studies that did not test the peptide alone14

In this study, the peptide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking the peptide.

03HumanNot a test of Liraglutide aloneSystematic reviewEfficacy outcome
In a meta-analysis of mixed populations with and without diabetes, pooled GLP-1 therapy was associated with greater weight loss than placebo.
In plain wordsIn a review of mixed populations with and without diabetes, pooled GLP-1 treatment was linked to more weight loss than placebo.
Peptide
Liraglutide
Outcome
DecreaseWeight loss versus placebo
Study
n: not reported in source
Comparator
Placebo
Outcome group
Body weight · Metabolic and weight
Source sentences
Summary
GLP-1 therapy consistently produced greater weight loss than placebo across all populations.
4 context sentences(design, population, supporting numbers)
Summary · context
This study represents a subgroup analysis of a large-scale meta-analysis including clinical trials, observational and case-control studies published from 2010 to 2025 reporting long-term weight outcomes for GLP-1 agents.
Summary · context
Outcomes were evaluated across mixed, intention-to-treat (ITT), and treatment-adherent populations and stratified by diabetes status.
Summary · context
Mixed-effects meta-regression was performed to evaluate independent predictors of weight loss.
Summary · context
Semaglutide produced significantly greater reductions than liraglutide after adjustment (β = + 1.67, p < 0.001), while baseline BMI was inversely associated with percent weight change (β = + 0.46, p < 0.001).
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-4226017101
04HumanNot a test of Semaglutide aloneSystematic reviewEfficacy outcome
In a meta-analysis of mixed populations with and without diabetes, pooled GLP-1 therapy was associated with greater weight loss than placebo.
In plain wordsIn a review of mixed populations with and without diabetes, pooled GLP-1 treatment was linked to more weight loss than placebo.
Peptide
Semaglutide
Outcome
DecreaseWeight loss versus placebo
Study
n: not reported in source
Comparator
Placebo
Outcome group
Body weight · Metabolic and weight
Source sentences
Summary
GLP-1 therapy consistently produced greater weight loss than placebo across all populations.
4 context sentences(design, population, supporting numbers)
Summary · context
This study represents a subgroup analysis of a large-scale meta-analysis including clinical trials, observational and case-control studies published from 2010 to 2025 reporting long-term weight outcomes for GLP-1 agents.
Summary · context
Outcomes were evaluated across mixed, intention-to-treat (ITT), and treatment-adherent populations and stratified by diabetes status.
Summary · context
Mixed-effects meta-regression was performed to evaluate independent predictors of weight loss.
Summary · context
Semaglutide produced significantly greater reductions than liraglutide after adjustment (β = + 1.67, p < 0.001), while baseline BMI was inversely associated with percent weight change (β = + 0.46, p < 0.001).
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-4226017102
05HumanNot a test of Liraglutide aloneSystematic reviewEfficacy outcome
In the mixed cohort of a meta-analysis, pooled GLP-1 therapy was associated with 15.7% baseline-weight loss at 12 months in non-diabetic participants versus 5.1% in diabetic users.
In plain wordsIn a review, pooled GLP-1 treatment was linked to more 12-month weight loss without diabetes than with diabetes.
Peptide
Liraglutide
Outcome
DecreaseWeight loss by diabetes status at 12 months
Study
n: not reported in source
Comparator
Diabetic users
Outcome group
Body weight · Metabolic and weight
Measurements
Weight loss
15.7%
non-diabetic participants at 12 months
Weight loss
5.1%
diabetic users at 12 months
Source sentences
Summary
Non-diabetic participants achieved the greatest reductions, losing 15.7% of baseline weight at 12 months versus 5.1% in diabetic users in the mixed cohort.
4 context sentences(design, population, supporting numbers)
Summary · context
This study represents a subgroup analysis of a large-scale meta-analysis including clinical trials, observational and case-control studies published from 2010 to 2025 reporting long-term weight outcomes for GLP-1 agents.
Summary · context
Outcomes were evaluated across mixed, intention-to-treat (ITT), and treatment-adherent populations and stratified by diabetes status.
Summary · context
Mixed-effects meta-regression was performed to evaluate independent predictors of weight loss.
Summary · context
Semaglutide produced significantly greater reductions than liraglutide after adjustment (β = + 1.67, p < 0.001), while baseline BMI was inversely associated with percent weight change (β = + 0.46, p < 0.001).
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-4226017103
06HumanNot a test of Semaglutide aloneSystematic reviewEfficacy outcome
In the mixed cohort of a meta-analysis, pooled GLP-1 therapy was associated with 15.7% baseline-weight loss at 12 months in non-diabetic participants versus 5.1% in diabetic users.
In plain wordsIn a review, pooled GLP-1 treatment was linked to more 12-month weight loss without diabetes than with diabetes.
Peptide
Semaglutide
Outcome
DecreaseWeight loss by diabetes status at 12 months
Study
n: not reported in source
Comparator
Diabetic users
Outcome group
Body weight · Metabolic and weight
Measurements
Weight loss
15.7%
non-diabetic participants at 12 months
Weight loss
5.1%
diabetic users at 12 months
Source sentences
Summary
Non-diabetic participants achieved the greatest reductions, losing 15.7% of baseline weight at 12 months versus 5.1% in diabetic users in the mixed cohort.
4 context sentences(design, population, supporting numbers)
Summary · context
This study represents a subgroup analysis of a large-scale meta-analysis including clinical trials, observational and case-control studies published from 2010 to 2025 reporting long-term weight outcomes for GLP-1 agents.
Summary · context
Outcomes were evaluated across mixed, intention-to-treat (ITT), and treatment-adherent populations and stratified by diabetes status.
Summary · context
Mixed-effects meta-regression was performed to evaluate independent predictors of weight loss.
Summary · context
Semaglutide produced significantly greater reductions than liraglutide after adjustment (β = + 1.67, p < 0.001), while baseline BMI was inversely associated with percent weight change (β = + 0.46, p < 0.001).
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-4226017104
07HumanNot a test of Liraglutide aloneSystematic reviewEfficacy outcome
In a meta-analysis of populations with and without diabetes, pooled GLP-1 therapy was associated with the largest weight reductions among adherent patients.
In plain wordsIn a review of people with and without diabetes, pooled GLP-1 treatment was linked to the largest weight reductions among adherent patients.
Peptide
Liraglutide
Outcome
DecreaseWeight loss in adherent patients
Study
n: not reported in source
Outcome group
Body weight · Metabolic and weight
Source sentences
Summary
ITT results were similar but modestly attenuated, whereas adherent patients demonstrated the largest reductions.
4 context sentences(design, population, supporting numbers)
Summary · context
This study represents a subgroup analysis of a large-scale meta-analysis including clinical trials, observational and case-control studies published from 2010 to 2025 reporting long-term weight outcomes for GLP-1 agents.
Summary · context
Outcomes were evaluated across mixed, intention-to-treat (ITT), and treatment-adherent populations and stratified by diabetes status.
Summary · context
Mixed-effects meta-regression was performed to evaluate independent predictors of weight loss.
Summary · context
Semaglutide produced significantly greater reductions than liraglutide after adjustment (β = + 1.67, p < 0.001), while baseline BMI was inversely associated with percent weight change (β = + 0.46, p < 0.001).
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-4226017105
08HumanNot a test of Semaglutide aloneSystematic reviewEfficacy outcome
In a meta-analysis of populations with and without diabetes, pooled GLP-1 therapy was associated with the largest weight reductions among adherent patients.
In plain wordsIn a review of people with and without diabetes, pooled GLP-1 treatment was linked to the largest weight reductions among adherent patients.
Peptide
Semaglutide
Outcome
DecreaseWeight loss in adherent patients
Study
n: not reported in source
Outcome group
Body weight · Metabolic and weight
Source sentences
Summary
ITT results were similar but modestly attenuated, whereas adherent patients demonstrated the largest reductions.
4 context sentences(design, population, supporting numbers)
Summary · context
This study represents a subgroup analysis of a large-scale meta-analysis including clinical trials, observational and case-control studies published from 2010 to 2025 reporting long-term weight outcomes for GLP-1 agents.
Summary · context
Outcomes were evaluated across mixed, intention-to-treat (ITT), and treatment-adherent populations and stratified by diabetes status.
Summary · context
Mixed-effects meta-regression was performed to evaluate independent predictors of weight loss.
Summary · context
Semaglutide produced significantly greater reductions than liraglutide after adjustment (β = + 1.67, p < 0.001), while baseline BMI was inversely associated with percent weight change (β = + 0.46, p < 0.001).
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-4226017106
09HumanNot a test of Liraglutide aloneSystematic reviewEfficacy outcome
In a meta-analysis, non-diabetic individuals receiving the same pooled GLP-1 agents had 2.5-4 times greater weight reductions than diabetic individuals.
In plain wordsIn a review, pooled GLP-1 drugs were linked to greater weight reduction without diabetes than with diabetes.
Peptide
Liraglutide
Outcome
DecreaseDiabetes status as weight-loss effect modifier
Study
n: not reported in source
Comparator
Diabetic individuals receiving the same agents
Outcome group
Body weight · Metabolic and weight
Measurements
Relative weight-reduction magnitude
2.5 to 4 times
non-diabetic versus diabetic individuals receiving the same GLP-1 agents
Source sentences
Summary
Diabetes status was a strong effect modifier: non-diabetic individuals achieved 2.5-4 × greater reductions than diabetics receiving the same agents.
4 context sentences(design, population, supporting numbers)
Summary · context
This study represents a subgroup analysis of a large-scale meta-analysis including clinical trials, observational and case-control studies published from 2010 to 2025 reporting long-term weight outcomes for GLP-1 agents.
Summary · context
Outcomes were evaluated across mixed, intention-to-treat (ITT), and treatment-adherent populations and stratified by diabetes status.
Summary · context
Mixed-effects meta-regression was performed to evaluate independent predictors of weight loss.
Summary · context
Semaglutide produced significantly greater reductions than liraglutide after adjustment (β = + 1.67, p < 0.001), while baseline BMI was inversely associated with percent weight change (β = + 0.46, p < 0.001).
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-4226017107
10HumanNot a test of Semaglutide aloneSystematic reviewEfficacy outcome
In a meta-analysis, non-diabetic individuals receiving the same pooled GLP-1 agents had 2.5-4 times greater weight reductions than diabetic individuals.
In plain wordsIn a review, pooled GLP-1 drugs were linked to greater weight reduction without diabetes than with diabetes.
Peptide
Semaglutide
Outcome
DecreaseDiabetes status as weight-loss effect modifier
Study
n: not reported in source
Comparator
Diabetic individuals receiving the same agents
Outcome group
Body weight · Metabolic and weight
Measurements
Relative weight-reduction magnitude
2.5 to 4 times
non-diabetic versus diabetic individuals receiving the same GLP-1 agents
Source sentences
Summary
Diabetes status was a strong effect modifier: non-diabetic individuals achieved 2.5-4 × greater reductions than diabetics receiving the same agents.
4 context sentences(design, population, supporting numbers)
Summary · context
This study represents a subgroup analysis of a large-scale meta-analysis including clinical trials, observational and case-control studies published from 2010 to 2025 reporting long-term weight outcomes for GLP-1 agents.
Summary · context
Outcomes were evaluated across mixed, intention-to-treat (ITT), and treatment-adherent populations and stratified by diabetes status.
Summary · context
Mixed-effects meta-regression was performed to evaluate independent predictors of weight loss.
Summary · context
Semaglutide produced significantly greater reductions than liraglutide after adjustment (β = + 1.67, p < 0.001), while baseline BMI was inversely associated with percent weight change (β = + 0.46, p < 0.001).
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-4226017108
11HumanNot a test of Liraglutide aloneSystematic reviewOther
In a meta-analysis of pooled GLP-1 therapy, diabetes status was an independent negative predictor of weight loss.
In plain wordsIn a review, diabetes was linked to less weight loss with pooled GLP-1 therapy.
Peptide
Liraglutide
Outcome
DecreaseDiabetes status as predictor of weight loss
Study
n: not reported in source
Outcome group
Body weight · Metabolic and weight
Measurements
Beta
−1.77
diabetes status; P<0.001
Source sentences
Summary
Meta-regression confirmed diabetes status as an independent negative predictor of weight loss (β = - 1.77, p < 0.001).
4 context sentences(design, population, supporting numbers)
Summary · context
This study represents a subgroup analysis of a large-scale meta-analysis including clinical trials, observational and case-control studies published from 2010 to 2025 reporting long-term weight outcomes for GLP-1 agents.
Summary · context
Outcomes were evaluated across mixed, intention-to-treat (ITT), and treatment-adherent populations and stratified by diabetes status.
Summary · context
Mixed-effects meta-regression was performed to evaluate independent predictors of weight loss.
Summary · context
Semaglutide produced significantly greater reductions than liraglutide after adjustment (β = + 1.67, p < 0.001), while baseline BMI was inversely associated with percent weight change (β = + 0.46, p < 0.001).
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-4226017109
12HumanNot a test of Semaglutide aloneSystematic reviewOther
In a meta-analysis of pooled GLP-1 therapy, diabetes status was an independent negative predictor of weight loss.
In plain wordsIn a review, diabetes was linked to less weight loss with pooled GLP-1 therapy.
Peptide
Semaglutide
Outcome
DecreaseDiabetes status as predictor of weight loss
Study
n: not reported in source
Outcome group
Body weight · Metabolic and weight
Measurements
Beta
−1.77
diabetes status; P<0.001
Source sentences
Summary
Meta-regression confirmed diabetes status as an independent negative predictor of weight loss (β = - 1.77, p < 0.001).
4 context sentences(design, population, supporting numbers)
Summary · context
This study represents a subgroup analysis of a large-scale meta-analysis including clinical trials, observational and case-control studies published from 2010 to 2025 reporting long-term weight outcomes for GLP-1 agents.
Summary · context
Outcomes were evaluated across mixed, intention-to-treat (ITT), and treatment-adherent populations and stratified by diabetes status.
Summary · context
Mixed-effects meta-regression was performed to evaluate independent predictors of weight loss.
Summary · context
Semaglutide produced significantly greater reductions than liraglutide after adjustment (β = + 1.67, p < 0.001), while baseline BMI was inversely associated with percent weight change (β = + 0.46, p < 0.001).
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-4226017110
13HumanNot a test of Liraglutide aloneSystematic reviewEfficacy outcome
In a meta-analysis of populations with and without diabetes, pooled GLP-1 therapy had similar but modestly attenuated weight-loss results in intention-to-treat populations.
In plain wordsIn a review of people with and without diabetes, pooled GLP-1 treatment had slightly less weight loss in intention-to-treat analyses.
Peptide
Liraglutide
Outcome
DecreaseWeight loss in intention-to-treat populations
Study
n: not reported in source
Outcome group
Body weight · Metabolic and weight
Source sentences
Summary
ITT results were similar but modestly attenuated, whereas adherent patients demonstrated the largest reductions.
4 context sentences(design, population, supporting numbers)
Summary · context
This study represents a subgroup analysis of a large-scale meta-analysis including clinical trials, observational and case-control studies published from 2010 to 2025 reporting long-term weight outcomes for GLP-1 agents.
Summary · context
Outcomes were evaluated across mixed, intention-to-treat (ITT), and treatment-adherent populations and stratified by diabetes status.
Summary · context
Mixed-effects meta-regression was performed to evaluate independent predictors of weight loss.
Summary · context
Semaglutide produced significantly greater reductions than liraglutide after adjustment (β = + 1.67, p < 0.001), while baseline BMI was inversely associated with percent weight change (β = + 0.46, p < 0.001).
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-4226017112
14HumanNot a test of Semaglutide aloneSystematic reviewEfficacy outcome
In a meta-analysis of populations with and without diabetes, pooled GLP-1 therapy had similar but modestly attenuated weight-loss results in intention-to-treat populations.
In plain wordsIn a review of people with and without diabetes, pooled GLP-1 treatment had slightly less weight loss in intention-to-treat analyses.
Peptide
Semaglutide
Outcome
DecreaseWeight loss in intention-to-treat populations
Study
n: not reported in source
Outcome group
Body weight · Metabolic and weight
Source sentences
Summary
ITT results were similar but modestly attenuated, whereas adherent patients demonstrated the largest reductions.
4 context sentences(design, population, supporting numbers)
Summary · context
This study represents a subgroup analysis of a large-scale meta-analysis including clinical trials, observational and case-control studies published from 2010 to 2025 reporting long-term weight outcomes for GLP-1 agents.
Summary · context
Outcomes were evaluated across mixed, intention-to-treat (ITT), and treatment-adherent populations and stratified by diabetes status.
Summary · context
Mixed-effects meta-regression was performed to evaluate independent predictors of weight loss.
Summary · context
Semaglutide produced significantly greater reductions than liraglutide after adjustment (β = + 1.67, p < 0.001), while baseline BMI was inversely associated with percent weight change (β = + 0.46, p < 0.001).
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-4226017113
15HumanNot a test of Liraglutide aloneSystematic reviewOther
In a meta-analysis of populations with and without diabetes receiving pooled GLP-1 therapy, baseline BMI was described as inversely associated with percent weight change, while beta +0.46 was printed (P<0.001).
In plain wordsIn a review of people with and without diabetes, starting BMI was inversely linked to percentage weight change; the printed beta was positive.
Peptide
Liraglutide
Outcome
DecreaseBaseline BMI as predictor of percent weight change
Study
n: not reported in source
Outcome group
Body weight · Metabolic and weight
Measurements
Beta
0.46
baseline BMI; p<0.001
Source sentences
Summary
Semaglutide produced significantly greater reductions than liraglutide after adjustment (β = + 1.67, p < 0.001), while baseline BMI was inversely associated with percent weight change (β = + 0.46, p < 0.001).
3 context sentences(design, population, supporting numbers)
Summary · context
This study represents a subgroup analysis of a large-scale meta-analysis including clinical trials, observational and case-control studies published from 2010 to 2025 reporting long-term weight outcomes for GLP-1 agents.
Summary · context
Outcomes were evaluated across mixed, intention-to-treat (ITT), and treatment-adherent populations and stratified by diabetes status.
Summary · context
Mixed-effects meta-regression was performed to evaluate independent predictors of weight loss.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-4226017114
16HumanNot a test of Semaglutide aloneSystematic reviewOther
In a meta-analysis of populations with and without diabetes receiving pooled GLP-1 therapy, baseline BMI was described as inversely associated with percent weight change, while beta +0.46 was printed (P<0.001).
In plain wordsIn a review of people with and without diabetes, starting BMI was inversely linked to percentage weight change; the printed beta was positive.
Peptide
Semaglutide
Outcome
DecreaseBaseline BMI as predictor of percent weight change
Study
n: not reported in source
Outcome group
Body weight · Metabolic and weight
Measurements
Beta
0.46
baseline BMI; p<0.001
Source sentences
Summary
Semaglutide produced significantly greater reductions than liraglutide after adjustment (β = + 1.67, p < 0.001), while baseline BMI was inversely associated with percent weight change (β = + 0.46, p < 0.001).
3 context sentences(design, population, supporting numbers)
Summary · context
This study represents a subgroup analysis of a large-scale meta-analysis including clinical trials, observational and case-control studies published from 2010 to 2025 reporting long-term weight outcomes for GLP-1 agents.
Summary · context
Outcomes were evaluated across mixed, intention-to-treat (ITT), and treatment-adherent populations and stratified by diabetes status.
Summary · context
Mixed-effects meta-regression was performed to evaluate independent predictors of weight loss.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-4226017115

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 3Current
12 Oct 2026, 11:11 UTC
Study results updated
Version 2
9 Oct 2026, 03:06 UTC
Study data updated · source update from Europe PMC
Version 1
9 Oct 2026, 03:04 UTC
First added · source update from Europe PMC

Differential impact of glucagon-like peptide-1 (GLP-1) receptor agonists for weight loss in the type 2 diabetic and non-diabetic populations.

Summary

Results from this study16

Studies that did not test the peptide alone14

Version history

Subjects

Publication types

MeSH terms

Keywords